ONCOZENGE
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer patients.
ONCOZENGE
Industry:
Health Care Pharmaceutical
Address:
Bromma, Sodermanlands Lan, Sweden
Country:
Sweden
Website Url:
http://www.oncozenge.se
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Wordpress Plugins Mobile Non Scaleable Content Nginx
Similar Organizations
Oxford Vacmedix
Develop therapeutic agents for the treatment of cancer .
Official Site Inspections
http://www.oncozenge.se
- Host name: webfront4.webcluster.loopia.se
- IP address: 93.188.2.54
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "OncoZenge"
Investors - OncoZenge
OncoZenge is developing BupiZenge ... He is a founder of Biomodels, a pre-clinical research organization, which was spun out of Brigham and Women’s Hospital in 1997 and has assisted …See details»
Home - OncoZenge
The Phase 2 clinical trial results reported by OncoZenge suggest that a novel topical formulation of bupivacaine might offer a safe and effective, non-opioid alternative to mitigating mucositis-associated pain. I look forward to …See details»
OncoZenge - Crunchbase Company Profile & Funding
Organization. OncoZenge . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; OncoZenge is a …See details»
OncoZenge AB Company Description - Stock Analysis
Nov 19, 2024 OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and …See details»
Company OncoZenge AB - MarketScreener.com
OncoZenge AB is a Sweden-based pharmaceutical company, that develops products for cancer supportive care. OncoZenge's vision is to improve the quality of life for patients with severe …See details»
OncoZenge AB - LinkedIn
OncoZenge AB has entered into a conditional bridge financing agreement of SEK 10 million through a convertible loan with one of its major shareholders, Linc AB.The agreement is …See details»
Company OncoZenge AB (publ) Nasdaq Stockholm
Sep 8, 2023 OncoZenge AB is a Sweden-based pharmaceutical company, that develops products for cancer supportive care. OncoZenge's vision is to improve the quality of life for …See details»
Internal control - oncozenge.se
OncoZenge’s board and management define and design decision paths, authorities, and responsibilities that are clearly defined and communicated within the organization. The …See details»
OncoZenge Company Profile 2024: Stock Performance …
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the …See details»
OncoZenge - Products, Competitors, Financials, Employees, …
OncoZenge's lozenges are based on the active substance bupivacaine, offering significant pain relief and quality of life improvements for affected patients. It was founded in 2020 and is …See details»
OncoZenge - Overview, News & Similar companies | ZoomInfo.com
OncoZenge participates in MASCC cancer care conference June 27-29 Stockholm, Sweden – June 4 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing …See details»
Contact us - OncoZenge
For general inquiries contact us at [email protected]. [email protected]. Media. For media or investor queries please contact our CEO Stian Kildal. [email protected]. Mailing …See details»
Oncozenge AB, ONCOZ:STO profile - FT.com - Financial Times
OncoZenge AB is a Sweden-based pharmaceutical company, that develops products for cancer supportive care. OncoZenge's vision is to improve the quality of life for patients with severe …See details»
OncoZenge secures approximately SEK 70 million in financing …
Dec 15, 2020 Moberg Pharma’s subsidiary OncoZenge has received binding undertakings regarding a directed issue of shares of SEK 10 million and a fully secured rights issue of …See details»
OncoZenge secures approximately SEK 70 million in financing
Nov 16, 2020 For additional information, please contact: Pirkko Tamsen, CEO OncoZenge, telephone: +46 760 09 84 99, e-mail: [email protected] Anna Ljung, CEO Moberg …See details»
OncoZenge secures approximately SEK 70 million in financing …
Nov 16, 2020 Pirkko Tamsen, CEO OncoZenge, telephone: +46 760 09 84 99, e-mail: [email protected] Anna Ljung, CEO Moberg Pharma, telephone: +46 707 66 60 …See details»
OncoZenge: Back on track - redeye.se
Oct 31, 2024 OncoZenge: Back on track. Coverage Initiation. 2024-10-31. 07:00. Redeye initiates coverage of OncoZenge, a Swedish biotech company offering an innovative solution …See details»
OncoZenge expands the board with Hilde Furberg - OncoZenge
Pirkko Tamsen, CEO OncoZenge, telephone: +46 760 09 84 99, e-mail: [email protected]. About this information The information was submitted for …See details»
OncoZenge provides strategy update - OncoZenge
With that backdrop OncoZenge provides the following strategy update with focus on market potential and strategic partnering for accelerating BupiZenge™ towards market approval. As …See details»
OncoZenge secures approximately SEK 70 million in ... - Moberg …
Nov 16, 2020 Pirkko Tamsen, CEO OncoZenge, telephone: +46 760 09 84 99, e-mail: [email protected] Anna Ljung, CEO Moberg Pharma, telephone: +46 707 66 60 …See details»